Activation of B cells is a hallmark of systemic lupus erythematosus (SLE). Syk and TRAF6 are key signaling molecules in B-cell activation through BCR and CD40/TLR, respectively. Nevertheless, whether expression of Syk and TRAF6 is altered in SLE B cells remains unknown.
Methods
Phosphorylation and/or expression of Syk and TRAF6 were analyzed by flow cytometry in peripheral blood mononuclear cells isolated from SLE patients.
Results
Pronounced phosphorylation and expression of Syk were noted in B cells from SLE patients compared with healthy donors. Levels of Syk phosphorylation correlated with the disease activity score. TRAF6 was significantly over-expressed in B cells of SLE patients as compared with healthy donors, and significant correlation of levels of TRAF6 expression and Syk phosphorylation was observed in SLE patients. Levels of TRAF6 expression were more pronounced in CD27+ memory B cells than in CD27-naïve B cells. In vitro treatment of SLE B cells with a Syk inhibitor (BAY61-3606) reduced Syk phosphorylation as well as TRAF6 expression.
Conclusion
Our results suggest that the activated Syk-mediated TRAF6 pathway leads to aberrant activation of B cells in SLE, and also highlight Syk as a potential target for B-cell-mediated processes in SLE.
MartinFChanAC. B cell immunobiology in disease: Evolving concepts from the clinic. Annu Rev Immunol2006; 24: 467–496.
2.
TaniguchiTKobayashiTKondoJ. Molecular cloning of a porcine gene syk that encodes a 72-kDa protein-tyrosine kinase showing high susceptibility to proteolysis. J Biol Chem1991; 266: 15790–15796.
3.
WongWSLeongKP. Tyrosine kinase inhibitors: A new approach for asthma. Biochim Biophys Acta2004; 1697: 53–69.
4.
BeavenMABaumgartnerRA. Downstream signals initiated in mast cells by Fc epsilon RI and other receptors. Curr Opin Immunol1996; 8: 766–772.
5.
MeltzerEOBerkowitzRBGrossbardEB. An intranasal Syk-kinase inhibitor (R112) improves the symptoms of seasonal allergic rhinitis in a park environment. J Allergy Clin Immunol2005; 115: 791–796.
6.
BajpaiM. Fostamatinib, a Syk inhibitor prodrug for the treatment of inflammatory diseases. IDrugs2009; 12: 174–185.
7.
PodolanczukALazarusAHCrowARGrossbardEBusselJB. Of mice and men: An open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk. Blood2009; 113: 3154–3160.
8.
WeinblattMEKavanaughABurgos-VargasR. Treatment of rheumatoid arthritis with a Syk kinase inhibitor: A twelve-week, randomized, placebo-controlled trial. Arthritis Rheum2008; 58: 3309–3318.
9.
WeinblattMEKavanaughAGenoveseMCMusserTKGrossbardEBMagilavyDB. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N Engl J Med2010; 363: 1303–1312.
10.
BahjatFRPinePRReitsmaA. An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus. Arthritis Rheum2008; 58: 1433–1444.
11.
DengGMLiuLBahjatFRPinePRTsokosGC. Suppression of skin and kidney disease by inhibition of spleen tyrosine kinase in lupus-prone mice. Arthritis Rheum2010; 62: 2086–2092.
12.
KulathuYGrotheGRethM. Autoinhibition and adapter function of Syk. Immunol Rev2009; 232: 286–299.
13.
RuprechtCRLanzavecchiaA. Toll-like receptor stimulation as a third signal required for activation of human naïve B cells. Eur J Immunol2006; 36: 810–816.
14.
Desai-MehtaALuLRamsey-GoldmanRDattaSK. Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production. J Clin Invest1996; 97: 2063–2073.
15.
EhlersMFukuyamaHMcGahaTLAderemARavetchJV. TLR9/MyD88 signaling is required for class switching to pathogenic IgG2a and 2b autoantibodies in SLE. J Exp Med2006; 203: 553–561.
16.
KriegAM. A role for Toll in autoimmunity. Nat Immunol2002; 3: 423–424.
17.
RowlandSLTremblayMMEllisonJMStunzLLBishopGAHostagerBS. A novel mechanism for TNFR-associated factor 6-dependent CD40 signaling. J Immunol2007; 179: 4645–4653.
18.
JalukarSVHostagerBSBishopGA. Characterization of the roles of TNF receptor-associated factor 6 in CD40-mediated B lymphocyte effector functions. J Immunol2000; 164: 623–630.
19.
IwataSYamaokaKNiiroH. Amplification of toll-like receptor-mediated signaling through Syk in human B cell activation. J Allergy Clin Immunol2012; 129: 1594–1601.
20.
HochbergMC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1997; 40: 1725–1725.
21.
HayEMBaconPAGordonC. The BILAG index: A reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med1993; 86: 447–458.
22.
BencivelliWVitaliCIsenbergDA. Disease activity in systemic lupus erythematosus: Report of the Consensus Study Group of the European Workshop for Rheumatology Research. III. Development of a computerised clinical chart and its application to the comparison of different indices of disease activity. The European Consensus Study Group for Disease Activity in SLE. Clin Exp Rheumatol1992; 10: 549–554.
23.
LiossisSNKovacsBDennisGKammerGMTsokosGC. B cells from patients with systemic lupus erythematosus display abnormal antigen receptor-mediated early signal transduction events. J Clin Invest1996; 98: 2549–2557.
24.
NicholasMWDooleyMAHoganSL. A novel subset of memory B cells is enriched in autoreactivity and correlates with adverse outcomes in SLE. Clin Immunol2008; 126: 189–201.
25.
FujimotoMPoeJCJansenPJSatoSTedderTF. CD19 amplifies B lymphocyte signal transduction by regulating Src-family protein tyrosine kinase activation. J Immunol1999; 162: 7088–7094.
26.
BishopGA. The multifaceted roles of TRAFs in the regulation of B cell function. Nat Rev Immunol2004; 4: 775–786.
27.
KobayashiTKimTSJacobA. TRAF6 is required for generation of the B-1a B cell compartment as well as T cell-dependent and -independent humoral immune responses. PLoS One2009; 4: e4736–e4736.
28.
NamjouBChoiCBHarleyIT. Evaluation of TRAF6 in a large multi-ancestral lupus cohort. Arthritis Rheum2012; 64: 1960–1969.
29.
JacobiAMReiterKMackayM. Activated memory B cell subsets correlate with disease activity in systemic lupus erythematosus: delineation by expression of CD27, IgD, and CD95. Arthritis Rheum2008; 58: 1762–1773.
30.
IwataSSaitoKTokunagaM. Phenotypic changes of lymphocytes in patients with systemic lupus erythematosus who are in long-term remission after B cell depletion therapy with rituximab. J Rheumatol2011; 38: 633–641.
31.
IwataSSaitoKTokunagaMTanakaY. B-cell or T-cell-dominant recurrence after rituximab therapy in patients with SLE. Ann Rheum Dis2012; 71: 1749–1750.
32.
BernasconiNLOnaiNLanzavecchiaA. A role for Toll-like receptors in acquired immunity: Up-regulation of TLR9 by BCR triggering in naive B cells and constitutive expression in memory B cells. Blood2003; 101: 4500–4504.
